Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Bladder cancer remains a leading cause of cancer death worldwide and is associated with
substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with
heterogeneous clinical outcomes. Several molecular classifications have been proposed …

Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75–
85% of patients with bladder cancer present with a disease that is confined to the mucosa …

Urothelial carcinoma (UC), the sixth most common cancer in Western countries, includes
upper tract urothelial carcinoma (UTUC) and bladder carcinoma (BC) as the most common …

The recommended treatment for patients with high-risk non–muscle-invasive bladder cancer
(HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) …

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

Aim This review article summarizes the current clinical practice guidelines around disease
definitions and risk stratifications, and the treatment of non-muscle-invasive bladder cancer …

Whole-genome analyses have revealed that muscle-invasive bladder cancers (MIBCs) are
heterogeneous and can be grouped into basal and luminal subtypes that are highly …